Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Grows By 55.8%

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 112,375 shares, an increase of 55.8% from the March 15th total of 72,125 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 17 shares, the days-to-cover ratio is currently 6,610.3 days.

Newron Pharmaceuticals Stock Performance

Shares of OTCMKTS NWPHF opened at $20.00 on Tuesday. The firm has a 50 day moving average price of $11.49 and a 200 day moving average price of $10.11. Newron Pharmaceuticals has a 52-week low of $9.10 and a 52-week high of $20.00.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.